-
Press Release
Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company
-
Press Release
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
-
Press Release
Novartis verzeichnet ein starkes zweites Quartal mit zweistelligem Umsatzwachstum und erhöhter Kerngewinnmarge; Prognose für das operative Kernergebnis im Geschäftsjahr 2025 angehoben
-
Press Release
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
-
Press Release
Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1
-
Press Release
Novartis setzt die starke Dynamik fort mit zweistelligem Umsatzwachstum, robusten Margensteigerungen und mehreren Zulassungen im ersten Quartal
-
Press Release
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
-
Press Release
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
-
Press Release
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
-
Press Release
Novartis setzt die starke Umsatzdynamik mit Margenerhöhungen fort und erreicht 2024 wichtige Meilensteine bei Innovationen
-
Press Release
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
-
Press Release
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth